These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36385558)

  • 1. Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma in vitro and in vivo by impairing SIAH1-mediated mitophagy.
    Zhou J; Feng J; Wu Y; Dai HQ; Zhu GZ; Chen PH; Wang LM; Lu G; Liao XW; Lu PZ; Su WJ; Hooi SC; Ye XP; Shen HM; Peng T; Lu GD
    Exp Mol Med; 2022 Nov; 54(11):2007-2021. PubMed ID: 36385558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting mitophagy as a novel therapeutic approach in liver cancer.
    Feng J; Zhou J; Wu Y; Shen HM; Peng T; Lu GD
    Autophagy; 2023 Jul; 19(7):2164-2165. PubMed ID: 36519332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human menstrual blood-derived stem cells reverse sorafenib resistance in hepatocellular carcinoma cells through the hyperactivation of mitophagy.
    Zhou S; Liu Y; Zhang Q; Xu H; Fang Y; Chen X; Fu J; Yuan Y; Li Y; Yuan L; Xiang C
    Stem Cell Res Ther; 2023 Apr; 14(1):58. PubMed ID: 37005657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ketoconazole exacerbates mitophagy to induce apoptosis by downregulating cyclooxygenase-2 in hepatocellular carcinoma.
    Chen Y; Chen HN; Wang K; Zhang L; Huang Z; Liu J; Zhang Z; Luo M; Lei Y; Peng Y; Zhou ZG; Wei Y; Huang C
    J Hepatol; 2019 Jan; 70(1):66-77. PubMed ID: 30287340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
    Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
    Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial.
    Chung YH; Han G; Yoon JH; Yang J; Wang J; Shao GL; Kim BI; Lee TY; Chao Y
    Int J Cancer; 2013 May; 132(10):2448-58. PubMed ID: 23129123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib.
    Zheng Y; Huang C; Lu L; Yu K; Zhao J; Chen M; Liu L; Sun Q; Lin Z; Zheng J; Chen J; Zhang J
    J Hematol Oncol; 2021 Jan; 14(1):16. PubMed ID: 33446239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy.
    Prieto-Domínguez N; Ordóñez R; Fernández A; Méndez-Blanco C; Baulies A; Garcia-Ruiz C; Fernández-Checa JC; Mauriz JL; González-Gallego J
    J Pineal Res; 2016 Oct; 61(3):396-407. PubMed ID: 27484637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
    Lencioni R; Llovet JM; Han G; Tak WY; Yang J; Guglielmi A; Paik SW; Reig M; Kim DY; Chau GY; Luca A; Del Arbol LR; Leberre MA; Niu W; Nicholson K; Meinhardt G; Bruix J
    J Hepatol; 2016 May; 64(5):1090-1098. PubMed ID: 26809111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results.
    Cosgrove DP; Reyes DK; Pawlik TM; Feng AL; Kamel IR; Geschwind JF
    Radiology; 2015 Nov; 277(2):594-603. PubMed ID: 26069923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
    Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
    Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
    Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitophagy promotes sorafenib resistance through hypoxia-inducible ATAD3A dependent Axis.
    Wu H; Wang T; Liu Y; Li X; Xu S; Wu C; Zou H; Cao M; Jin G; Lang J; Wang B; Liu B; Luo X; Xu C
    J Exp Clin Cancer Res; 2020 Dec; 39(1):274. PubMed ID: 33280610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.
    Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Kanai F; Yoshikawa M; Yokosuka O
    Oncology; 2014; 87(6):330-41. PubMed ID: 25227534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature.
    Abdel-Rahman O; Elsayed ZA
    Dig Dis Sci; 2013 Dec; 58(12):3389-96. PubMed ID: 24046163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Yang M; Yuan JQ; Bai M; Han GH
    Mol Biol Rep; 2014 Oct; 41(10):6575-82. PubMed ID: 25091939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
    Wang W; Bai W; Wang E; Zhao Y; Liu L; Yang M; Cai H; Xia D; Zhang L; Niu J; Yin Z; Zhang Z; Fan D; Xia J; Han G
    Int J Cancer; 2017 Jan; 140(2):390-399. PubMed ID: 27681592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and the strategy to treat the side effects of sorafenib administration after transarterial chemoembolization in advanced hepatocellular carcinoma patients.
    Zhang K; Sun X; Xie F; Jian W; Li C
    J Cancer Res Ther; 2018 Jan; 14(1):196-200. PubMed ID: 29516985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of transarterial chemoembolization and sorafenib improves outcomes of unresectable hepatocellular carcinoma: an updated systematic review and meta-analysis.
    Jin PP; Shao SY; Wu WT; Zhao XY; Huang BF; Fu QH; Que RS; Hu QD
    Jpn J Clin Oncol; 2018 Dec; 48(12):1058-1069. PubMed ID: 30272196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.